key: cord-0897869-g5lz17gq
authors: Chang, Sui-Yuan; Huang, Kuo-Yen; Chao, Tai-Ling; Kao, Han-Chieh; Pang, Yu-Hao; Lu, Lin; Chiu, Chun-Lun; Huang, Hsin-Chang; Cheng, Ting-Jen Rachel; Fang, Jim-Min; Yang, Pan-Chyr
title: Nanoparticle composite TPNT1 is effective against SARS-CoV-2 and influenza viruses
date: 2021-04-22
journal: Sci Rep
DOI: 10.1038/s41598-021-87254-3
sha: 346e8ad8bad4d086d2fec5b9915b613866785072
doc_id: 897869
cord_uid: g5lz17gq

A metal nanoparticle composite, namely TPNT1, which contains Au-NP (1 ppm), Ag-NP (5 ppm), ZnO-NP (60 ppm) and ClO(2) (42.5 ppm) in aqueous solution was prepared and characterized by spectroscopy, transmission electron microscopy, dynamic light scattering analysis and potentiometric titration. Based on the in vitro cell-based assay, TPNT1 inhibited six major clades of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with effective concentration within the range to be used as food additives. TPNT1 was shown to block viral entry by inhibiting the binding of SARS-CoV-2 spike proteins to the angiotensin-converting enzyme 2 (ACE2) receptor and to interfere with the syncytium formation. In addition, TPNT1 also effectively reduced the cytopathic effects induced by human (H1N1) and avian (H5N1) influenza viruses, including the wild-type and oseltamivir-resistant virus isolates. Together with previously demonstrated efficacy as antimicrobials, TPNT1 can block viral entry and inhibit or prevent viral infection to provide prophylactic effects against both SARS-CoV-2 and opportunistic infections.

In this study, we formulated a metal nanoparticle composite, TPNT1 as the stock solution, which contains Au-NP (1 ppm), Ag-NP (5 ppm), ZnO-NP (60 ppm) and ClO 2 (42.5 ppm) in aqueous solution with a positive zeta potential of + 32.81 mV. The individual metal nanoparticles were synthesized according to our patented method 15 . In brief, a metal aqueous solution (HAuCl 4 , AgNO 3 or ZnCl 2 ) was reduced by heating with citric acid at 150 °C for 12 min, and then dispersed in an appropriate medium to obtain the colloidal metal nanoparticles. The physicochemical properties of the synthesized nanoparticles were fully characterized by ultraviolet-visible spectroscopy, infrared spectroscopy, inductively coupled plasma atomic emission spectroscopy, transmission electron microscopy (TEM), dynamic light scattering (DLS) analysis and potentiometric titration (Fig. 1) . According to the TEM imaging, Au-NP, Ag-NP and ZnO-NP are in spherical shape with 20-40, 10-40 and 25-35 nm diameters, respectively. The average sizes of colloidal Au-NP, Ag-NP and ZnO-NP are 78.1, 50.4 and 619.1 nm as shown individually by the DLS analysis. A colloidal solution of nanoparticle composite, namely TPNT1, containing 1 ppm Au-NP, 5 ppm Ag-NP, 60 ppm ZnO-NP and 42.5 ppm chlorine dioxide (ClO 2 ) was prepared by well mixing of the above-described materials. www.nature.com/scientificreports/ The antiviral activity of TPNT1 against SARS-CoV-2 was first examined by plaque reduction assay. Briefly, Vero E6 cells were infected with SARS-CoV-2 (SARS-CoV-2/NTU01/TWN/human/2020) in the presence of various concentrations of TPNT1. As shown in Fig. 2a , an obvious reduction of plaque numbers was observed in the presence of 100-fold diluted TPNT1 containing 0.01 ppm Au-NP, 0.05 ppm Ag-NP, 0.6 ppm ZnO-NP, and 0.425 ppm ClO 2 . The calculated IC 50 for TPNT1 is 143 ± 15.5-fold dilution (Fig. 2b) . The cell toxicity of TPNT1 was determined by the acid phosphatase (ACP) assay 16 and the derived selectivity index (SI; CC 50 /IC 50 ) was greater than 10 ( Fig. 2b) . The ability of TPNT1 to inhibit various SARS-CoV-2 strains was subsequently determined using 7 additional clinical isolates representing 6 major clades of SARS-CoV-2 viruses (Fig. 2c) . The virus isolates used were summarized in Table 1 . NTU01, NTU03, NTU06, NTU13, NTU14, NTU16, NTU18, and NTU27 represent A, B.1, B.2.2, A3, B.1.1, B.1.5, A.1, and B lineages of SARS-CoV-2, respectively. Among the eight clinical isolates, three (NTU3, 14, and 16) contains the D614G mutation, which is circulating predominantly worldwide since March, 2020, and has been reported to exhibit increased viral infectivity 17 . As shown in Fig. 2d , TPNT1 could inhibit 93.5-100% of plaque formation by these SARS-CoV-2 strains. The ability of TPNT1 to inhibit virus replication was also examined using yield-reduction assay in a human lung adenocarcinoma cell line H1975 transduced with ACE2 (H1975-ACE2). The viral titers in the culture supernatants was determined by plaque assay. A significant inhibition of infectious virus titers in the culture supernatants was observed for all clinical isolates, including the D614G variants, in the presence of TPNT1 by plaque assay (Fig. 2e) . TPNT1 can also inhibit the viral nucleoprotein (NP) expression in H1975-ACE2 cells infected by these SARS-CoV-2 strains (Fig. 2f) .

Yield reduction assay was subsequently performed to determine the stage where TPNT1 might exert its effects by either pretreating the virus with TPNT1 (pretreat + infection), adding TPNT1 during (infection) or after virus infection (post-infection). The schematic illustration for experimental design was shown in Fig. 3a . The culture supernatants and cell lysates were harvested for subsequent analysis. The virus copy number in the culture supernatant was determined by quantitative real-time RT-PCR (qRT-PCR) (Fig. 3b) . The replication of virus in the infected cells was determined by quantification of intracellular viral mRNA and viral nucleocapsid protein (NP) expression using the qRT-PCR of oligo-dT amplified cDNA (Fig. 3c) , western blot analysis (Fig. 3d) , and immunofluorescence assay (Fig. 3e) , respectively. Based on the experimental results, pre-incubation of diluted TPNT1 with SARS-CoV-2 is required for efficient inhibition of SARS-CoV-2 replication. TPNT1 functioned at a stage before virus infection since the virus titers in the supernatants reduced significantly when TPNT1 was preincubated with virus before infection (Fig. 3b ). Corresponding reduction of intracellular viral RNA and viral NP protein expression was only observed in cells infected with TPNT1-pretreated viruses (Fig. 3c-e) .

The ability of TPNT1 to inhibit binding of SARS-CoV-2 spike protein to ACE2 receptor was also confirmed by the ELISA assay using ACE2-Fc-Biotin and spike protein. As shown in Fig. 4a , TPNT1 blocked spike protein from binding to ACE2-Fc-Biotin in a dose-dependent manner. Since syncytium formation is a step critical for virus entry after receptor binding, we also examined the ability of TPNT1 to inhibit syncytium formation. As shown in Fig. 4b , syncytium formation between 293 T/Spike/EGFP and H1975-ACE2 cells was inhibited significantly in the presence of TPNT1. The inhibition of syncytia formation was calculated by counting the 293 T/Spike/EGFP cells fused or unfused with H1975-ACE2 cells under an inverted fluorescence microscope. A significant reduction of syncytium formation was observed in the presence of TPNT1 as compared to the solvent (H 2 O) control (Fig. 4c) .

In addition to SARS-CoV-2, we also tested the antiviral activities of TPNT1 against influenza virus infection in cell-based assays. Although there are currently four FDA-approved influenza antiviral drugs, peramivir, zanamivir, oseltamivir phosphate, and baloxavir marboxil, drug-resistant viruses have emerged and new therapeutics targeting drug-resistant viruses are needed [18] [19] [20] [21] . In addition, the threat from avian influenza A virus to cause pandemics in human population cannot be ignored 22 . Therefore, the antiviral activity of TPNT1 against seasonal influenza A (H1N1) and avian influenza A virus (H5N1) was determined by measuring the cytopathic effects (CPE) induced by virus infection. The inhibitory effects of TPNT1 was examined using three different virus inputs, 4,500, 10,000, and 20,000 TCID 50 /mL. As shown in Fig. 5a and c, TPNT1 effectively relieved the cells from virus-induced cytopathic effects, and a very modest reduced inhibition by TPNT1 was observed when the cells were infected with extremely high viral loads (20,000 TCID 50 /mL). The activities of TPNT1 against oseltamivir-resistant influenza viruses were also examined ( Fig. 5b and d) . Similar inhibitory effects against wildtype and oseltamivir-resistant influenza viruses were observed, although a slightly reduced inhibition against oseltamivir-resistant H1N1 viruses was noticed.

The person-to-person contact through respiratory droplets generated by sneezing and coughing, or contaminated fomites from the infected individuals has been shown to be the major transmission route for SARS-CoV-2. Besides efficient use of protective personal equipment, such as masks, as well as keeping social distance, implementation of a more active prevention strategy is required to contain the SARS-CoV-2 pandemic. In this study, we demonstrated the efficiency of a metal nanoparticle composite, TPNT1, as the prophylactic of COVID-19 infection. In addition, the anti-influenza activity of TPNT1 was also examined because influenza virus, known to infect millions of people annually and causing severe diseases, especially in the elderly 23 , shares the similar transmission routes, clinical presentations and seasonal coincidence with SARS-CoV-2. Based on the in vitro cell-based assay, TPNT1 was shown to efficiently inhibit SARS-CoV-2 as well as human (H1N1) and avian (H5N1) influenza viruses, likely through blocking of the viral entry. Receptor binding represents a critical step for viral entry and subsequent virus replication in host cells. Interactions between the SARS-CoV-2 spike protein and the ACE2 receptor 24, 25 , and the hemagglutinin (HA) of avian and human influenza viruses with the 2,3-linked or 2,6-linked Neu5Ac receptor on host cells 26 have been shown to be essential for virus infection. www.nature.com/scientificreports/ We demonstrated zzthat TPNT1 can efficiently abrogate the binding of SARS-CoV-2 spike protein to the ACE2 receptor on host cells, and to prevent the formation of syncytial cells. These data supports that TPNT1 can block viral entry and subsequently prevent viral infection to provide prophylactic effects against both SARS-CoV-2 and influenza viruses. Metal nanoparticles with large surface area can conjugate modifiers to attain multivalent effect on targeting viruses. For example, the Au-NPs conjugated with multivalent sialic-acid-terminated glycerol dendrons can tightly bind influenza hemagglutinin, and thus interfere with the attachment of virus to host cell 27 . However, preparation of organic modifiers and encapsulation of nanoparticles usually require tremendous synthetic effort. In comparison, we used "naked" Au-NPs without bioconjugation, along with Ag-NPs, ZnO-NPs and ClO 2 , as an effective composite agent to inhibit the binding of viruses to host cell. The SARS-CoV-2 and influenza virions, having average diameters of 80-120 nm, are in the size range of nanoparticles 28, 29 . As TPNT1 is most effective by pre-incubation with viruses, one possible mechanism for the antiviral activity of TPNT1 may be attributable to bindings of virus surface glycoproteins with the metal nanoparticles, and thus preventing the virions from attachment to host cells 27, [30] [31] [32] [33] . Indeed, our experiments (Fig. 4 ) support that TPNT1 can block viral entry by inhibiting the binding of SARS-CoV-2 spike proteins to ACE2 receptor and to interfere with the syncytium formation. It has been suggested that nanoparticles can diminish virus entry by direct interaction with the sulfur-bearing residues on the viral surface 34 . Based on the sequence analysis, SARS-CoV-2 spike has 40 cysteine residues while influenza hemagglutinin has 15 cysteine residues. Moreover, TPNT1 has positive surface charge (+ 32.81 mV) that may also enhance the binding with virions 35 . Inclusion of ClO 2 as an oxidizing agent in TPNT1 nanometal composite is beneficial for virus inhibition. A previous report indicates that magnesium oxide nanoparticle (MgO-NP) impregnated with Cl 2 exhibits higher bactericidal activity than free Cl 2 or MgO-NP itself 36 . Another study shows that the combination of single-wall carbon nanotubes and NaOCl (or H 2 O 2 ) also displays a synergistic sporicidal effect 37 . We assume that the ClO 2 component in TPNT1 may render oxidative damage of virus surface, and thus provide enhanced effect for viral inhibition by the metal nanoparticles.

Although metal nanoparticles have been demonstrated to have a wide range of biomedical applications 38 , the toxicity is an issue of concern. Most metal nanoparticles have beneficial and adverse dual effects. The degree of toxicity varies by the type, shape, size, purity, concentration, administration method and exposure time of metal nanoparticles. The current available data from many research teams are insufficient, and some are even www.nature.com/scientificreports/ contradictory, to determine the adverse effects of metal nanoparticles on human health [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] . As the information of toxicological studies including bio-distribution and metabolism of nanosized particles are insufficient, the safe doses of Au-NP, Ag-NP and ZnO-NP for humans are not yet established by European Food Safety Authority (EFSA) or US Environmental Protection Agency (EPA). In this study, all the Au-NP, Ag-NP and ZnO-NP in TPNT1 are prepared in spherical form, and spherical metal nanoparticles are known to be non-toxic or less toxic than that in other shapes 49, 50 . Gold compounds have been used in medicine for decades and most studies on animal models support that AuNPs do not cause appreciable toxicity 51 . The previous studies showed that 0.1-2.0 mg/kg was a safe dose of Ag-NP for oral administration to mice and rats 52 . The recommended daily intake of zinc is 8-11 mg for adults, and ZnO-NP at low dose (100 mg/kg bwt/day) is beneficial 53 . The amounts of Au (< 0.01 ppm), Ag (< 0.05 ppm) and ZnO (< 0.6 ppm) in the 50% effective dose of TPNT1 tests are considered within the range of concentration to be used as food additives. The content of ClO 2 (< 0.425 ppm) is also within the safety concentration in drinking water 54, 55 . In summary, we have shown that TPNT1 could effectively inhibit different strains of SARS-CoV-2 as well as human H1N1 and avian H5N1 influenza viruses, including the oseltamivir-resistant H274Y strains. Although we do not know its detailed anti-entry mechanism, TPNT1 indeed showed broad spectrum of antiviral activities against various SARS-CoV-2 strains and human/avian influenza viruses. Considering its prophylactic application, inorganic metal nanoparticles-based TPNT1 will have a relatively lower tendency to induce resistant viruses compared with therapeutic organic drugs. We believe TPNT1 can provide prophylactic effects against SARS-CoV-2 and opportunistic infections which are frequently observed in patients suffering SARS-CoV-2 infection by oral gargling, nasal spray, nebulized inhalation or even systemic use after an appropriate clinical trial.

General. All the reagents were reagent grade and used as purchase without further purification. Tetrachlo- 15 . Tetrachloroauric acid (2.25 mL of 0.2 M aqueous solution, 0.45 mmol) and citric acid (360 mg, 1.87 mmol) were added via an inlet port into a double-necked flatbottomed 100 mL reaction flask and were mixed to form a mixture solution. Subsequently, the flat-bottomed flask was placed on a hot plate and heated at 130 ℃ for 20 min to perform a reduction reaction, which was monitored by the IR spectrometer. The reduction reaction produced a composition containing gold nanoparticles and HCl gas. At the same time, HCl gas was guided through the recovery port attached to the flat-bottomed flask and was trapped with 10 mL water in an Erlenmeyer flask for collection. Finally, 450 mL of pure water was used as a medium to disperse the gold nanoparticles in the flat-bottomed flask, and said solution was heated at 70 °C. For 10 min to obtain 100 ppm colloidal solution of gold nanoparticles, which showed the TEM size at 20-40 nm, the UV-Vis absorption band at λ max = 526 nm with optical density (OD) = 0.78, and the DLS size at 78.1 nm.

Silver nitrate (15 mL of 0.37 M aqueous solution, 5.5 mmol) and citric acid (4961 mg, 25.59 mmol) were added via an inlet port into a double-necked flat-bottomed 100 mL reaction flask and were mixed to form a mixture solution. Subsequently, the flat-bottomed flask was placed on a hot plat and heated at 150 °C for 35 min to perform a reduction reaction, which was monitored by the IR spectrometer. The reduction reaction produced a composition containing silver nanoparticles and NO 2 gas. At the same time, NO 2 gas produced from the reduction reaction was guided through the recovery port attached to the flat-bottomed flask and was trapped with 10 mL water in an Erlenmeyer flask for collection. Finally, an aqueous solution (5100 mL) of citric acid (4026 mg, 20.96 mmol) and NaOH (423 mg, 10.58 mmol) was used as a medium to disperse the silver nanoparticles in the flat-bottomed flask, and said solution was heated at 70 °C for 60 min to obtain 100 ppm colloidal solution of silver nanoparticles, which showed the TEM size at 10-40 nm, the UV-Vis absorption band at λ max = 395 nm with OD = 0.74, and the DLS size at 50.4 nm.

Zinc chloride (8 mL of 2 M aqueous solution, 16 mmol) and citric acid (3608 mg, 18.78 mmol) were added via an inlet port into a double-necked flat-bottomed 100 mL reaction flask and were mixed to form a mixture solution. Subsequently, the flat-bottomed flask was placed on a hot plat and heated at 150 °C for 20 min to perform a reduction reaction, which was monitored by the IR spectrometer. The reduction reaction produced a composition containing zinc nanoparticles and HCl gas. At the same time, HCl gas produced from the reduction reaction was guided through the recovery port attached to the flat-bottomed flask and was trapped with 10 mL water in an Erlenmeyer flask for collection. Finally Taiwan University) and was maintained in RPMI1640 containing 10% FBS. H1975 cells were transduced with lentivirus encoding full-length ACE2 before being used as target cells (H1975-ACE2) . The expression of ACE2 in H1975-ACE2 cells was described in more details in another recently submitted manuscript by our group 56 . All adherent cells were cultured at 37 °C in a humidified atmosphere containing 5% CO 2 and 20% O 2 . Sputum specimens obtained from SARS-CoV-2-infected patients were propagated in Vero E6 cells in DMEM supplemented with 2 μg/mL tosylsulfonyl phenylalanyl chloromethyl ketone (TPCK)-trypsin (Sigma-Aldrich). Culture supernatant was harvested when CPE were seen in more than 70% of cells, and viral titers were determined by a plaque assay. The virus isolates used in the current study were summarized in Table 1 . The experimental protocols were approved by the NTUH Research Ethics Committee (202002002RIND by Dr. Jann-Tay Wang), and the informed consent was obtained from all subjects.

Plaque reduction assay was performed in triplicate in 24-well tissue culture plates. SARS-CoV-2 (100-200 plaque forming unit, pfu/well) was incubated with TPNT1 for 1 h at 37 °C before adding to the cell monolayer for another one hour. Subsequently, virus-TPNT1 mixtures were removed and the cell monolayer was washed once with PBS before covering with media containing 1% methylcellulose for 5-7 days. The cells were fixed with 10% formaldehyde overnight. After removal of overlay media, the cells were stained with 0.5% crystal violet and the plaques were counted. The percentage of inhibition was calculated as [1 − (V D /V C )] × 100%, where V D and V C refer to the virus titer in the presence and absence of the compound, respectively. ddH 2 O was used to prepare serial dilution of TPNT1 and was used as solvent control. For yield reduction assay, the virus (multiplicity of infection, M.O.I. = 0.01) was pretreated with TPNT1 and was added to the Vero E6 cells (pretreat + infection), or TPNT1 was added during (infection) or after virus infection (post-infection). To determine the amount of SARS-CoV-2 virus RNA, RNA from the culture supernatants and cell extracts of infected cells were extracted, respectively, and was determined by qRT-PCR of E gene using the iTaq Universal Probes One-Step RT-PCR Kit (172-5140, Bio-Rad, USA) and the Applied Biosystems 7500 Real-Time PCR software (version 7500SDS v1.5.1). Plasmid containing partial E fragment was used as the standards to calculate the amount of viral load (copies/μL). Total cell lysates were prepared in lysis buffer (20 mM Tris, pH 7.5, 100 mM sodium chloride, 1% IGEPAL CA-630, 100 µM Na 3 VO 4 , 50 mM NaF, and 30 mM sodium pyrophosphate) for Western blotting. The primary antibodies used were anti-nucleoprotein (NP) of SARS-CoV-2 (40143-R019, Sino biological, 1:5s000) and anti-PCNA (Millipore Corporation, 1:5000). The infected cells from yield reduction assay were fixed, and then probed with a rabbit monoclonal antibody against the NP of SARS-CoV 2 (1:200; 40103-R019, Sinobiological, China) and FITC-labeled goat anti-rabbit IgG (1:300; Jackson ImmunoResearch, USA). The nuclei were stained with DAPI. All of the experiments involving SARS-CoV-2 virus were performed in the Biosafety Level-3 Laboratory of National Taiwan University College of Medicine.

Cell toxicity assay. Vero E6 cells were seeded to the 96-well culture plate at a concentration of 2 × 10 4 cells per well. Next day, each well was washed once with PBS before addition of DMEM containing 2% FBS and different concentrations of TPNT1. After 3 days of incubation at 37 °C, medium was removed and washed once with PBS. Then, buffer containing 0.1 M sodium acetate (pH = 5.0), 0.1% Triton X-100, and 5 mM p-nitrophenyl phosphate was added, and incubated at 37 °C for 30 min. After that, 1 N NaOH was added to stop the reaction. The absorbance was determined by ELISA reader at a wavelength of 405 nm. The percentage of cell viability was calculated using the following formula: cell viability % = [(At/As) × 100]%, where At and As refer to the absorbance of a tested concentration and cell control, respectively. The 50% cytotoxicity concentration (CC 50 ) was defined as the concentration reducing 50% of cell viability.

ACE2-Fc-biotin and spike binding by ELISA assay. The construction of ACE2-Fc-Biotin and the ELISA was described by our group previously 56 . Briefly, the 1-674 A.A. of the SARS-CoV-2 spike with humanized codons were PCR-amplified and fused with the Fc region of human IgG1 at its C-terminus as the tag. The soluble recombinant proteins generated by the Expi293F system (A14527, ThermoFisher Scientific, USA) were purified by Protein G Sepharose (Merck). The concentration and purity of recombinant proteins was determined by NanoDrop and polyacrylamide gel electrophoresis, respectively. The ELISA was established as described in our recently submitted manuscript. Briefly, 50 μL of 50 ng/mL purified 1-674 spike proteins were pre-coated onto the 96-well ELISA plate at 4 °C overnight. The plate was then washed three times with PBST (PBS containing 0.05% Tween-20) before blocking with blocking buffer (1% BSA, 0.05% NaN 3 and 5% sucrose in PBS) at room temperature for 30 min. The plate was washed three times with PBST, and the mixture of serially diluted ACE2-Fc-Biotin with or without TPNT1 was added to the 96-well plate for 1 h at 37 The 293 T/Spike/EGFP cells fused or unfused with H1975-ACE2 cells were counted under an inverted fluorescence microscope (Leica DMI 6000B fluorescence microscope). The percent inhibition of syncytia formation was calculated using the following formula: (100 − (H − L)/(E − L) × 100). H represents the total green fluorescent score in the individual picture. L represents the green fluorescent score in the negative control group with H1975-ACE2 replaced by H1975 as the target cells. E represents the green fluorescent score in each picture in TPNT1 group.

Determination of anti-influenza activities. The reassortant viruses Influenza A/WSN/33 (H1N1), Influenza A/WSN/33 (H1N1) (NA H274Y), Influenza NIBRG14 (H5N1), Influenza NIBRG14 (H5N1) (NA H274Y) were created using 12-plasmid system that is based on cotransfection of mammalian cells with 8 plasmids encoding virion sense RNA under the control of a human PolI promoter and 4 plasmids encoding mRNA encoding the RNP complex (PB1, PB2, PA, and nucleoprotein gene products) under the control of a PolII promoter 57, 58 . Except hemagglutinin and neuraminidase genes, all other genes for production of recombinant viruses were gene Influenza A/WSN/33. Influenza A/WSN/33 (H1N1) and Influenza A/WSN/33 (H1N1) (NA H274Y) were produced by incorporation of the hemagglutinin and neuraminidase from A/WSN/33 with a mutation of H274Y on neuraminidase to create Influenza A/WSN/33 (H1N1) (NA H274Y). A/Viet Nam/1194/2004 (H5N1) (NA wt), Influenza NIBRG14 (H5N1) (NA H274Y) were produced by incorporation of the hemagglutinin and neuraminidase from A/Vietnam/1194/2004, with a mutation of H274Y on neuraminidase to create Influenza NIBRG14 (H5N1) (NA H274Y). The TCID 50 (50% tissue culture infectious dose) was determined by incubation of serially diluted influenza virus in 100 μL solution with 100 μL of MDCK cells at 1 × 10 5 cells/mL in 96-well microplates. The infected cells were incubated at 37 °C under 5% CO 2 for 48-72 h and added to each well with 100 μL per well of CellTiter Aqueous Non-Radioactive Cell Proliferation Assay reagent (Promega). After incubation at 37 °C for 15 min, absorbance at 490 nm was read on a plate reader. Influenza virus TCID 50 was determined using the Reed-Müench method 59, 60 . To test the anti-influenza activities of TPNT1, influenza virus at indicated titers was mixed with TPNT1 at various dilutions for 1 h at room temperature. The mixtures were used to infect MDCK cells at 1 × 10 5 cells/mL in 96 wells. After 48 h of incubation at 37 °C under 5% CO 2 , the cytopathic effects were determined with CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay reagent (Promega). The experiments involving influenza viruses were performed in the Biosafety Level-2 Laboratory of Genomics Research Center, Academia Sinica. Statistical analysis. Data were expressed as the mean ± standard deviation (SD). A two-tailed Student's t-test was used for the comparison of continuous variables, and a P < 0.05 was considered statistically significant (P < 0.05*; P < 0.01**; P < 0.001***).

This manuscript has been deposited in the Research Square preprint platform and the pre-print link is https:// www. resea rchsq uare. com/ artic le/ rs-52066/ v1. All methods were carried out in accordance with relevant guidelines and regulations.

Coronavirus Disease (COVID-19) Pandemic

Discovering drugs to treat coronavirus disease 2019 (COVID-19)

Megatrial outshines other drug studies

Insights from nanomedicine into chloroquine efficacy against COVID-19

Compassionate use of Remdesivir for patients with severe Covid-19

Mode of antiviral action of silver nanoparticles against HIV-1

Silver nanoparticles as potential antiviral agents

Nanoparticles as potential new generation broad spectrum antimicrobial agents

Antibacterial activity of silver nanoparticles: a surface science insight

Strategic role of selected noble metal nanoparticles in medicine

Comparison of infectious agents susceptibility to photocatalytic effects of nanosized titanium and zinc oxides: a practical approach

Zinc and respiratory tract infections: perspectives for COVID19 (Review)

Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism

Thiol-modified gold nanoparticles for the inhibition of Mycobacterium smegmatis

Method of making colloidal metal nanoparticles

An acid phosphatase assay for quantifying the growth of adherent and nonadherent cells

Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus

In vitro neuraminidase inhibitory concentration (IC50) of four neuraminidase inhibitors in the Japanese 2018-19 season: comparison with the 2010-11 to 2017-18 seasons

Next-generation direct-acting influenza therapeutics

Emerging antiviral resistance

New flu antiviral candidate may thwart drug resistance

Avian influenza virus (H5N1): a threat to human health

Seasonal and pandemic influenza: 100 years of progress, still much to learn

A pneumonia outbreak associated with a new coronavirus of probable bat origin

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Influenza virus assembly and budding

Inhibition of influenza virus infection by multivalent sialic-acid-functionalized gold nanoparticles

Transmission electron microscopy imaging of SARS-CoV-2

Fine structure of influenza A virus observed by electron cryo-microscopy

Antiviral activity of silver nanoparticle/chitosan composites against H1N1 influenza A virus

Inhibition of H1N1 influenza virus infection by zinc oxide nanoparticles: another emerging application of nanomedicine

Inhibition effect of silver nanoparticles on herpes simplex virus 2

Nanoparticles as antiviral agents against adenoviruses

Porous gold nanoparticles for attenuating infectivity of influenza A virus

The effects of interfacial potential on antimicrobial propensity of ZnO nanoparticle

Metal oxide nanoparticles as bactericidal agents

Inactivation of Bacillus anthracis spores by single-walled carbon nanotubes coupled with oxidizing antimicrobial chemicals

Therapeutic gold, silver, and platinum nanoparticles

Assessment of the in vivo toxicity of gold nanoparticles

Decreased dissolution of ZnO by iron doping yields nanoparticles with reduced toxicity in the rodent lung and zebrafish embryos

In vivo human time-exposure study of orally dosed commercial silver nanoparticles

Blood biochemical and hematological study after subacute intravenous injection of gold and silver nanoparticles and coadministered gold and silver nanoparticles of similar sizes

Toxicity and biokinetics of colloidal gold nanoparticles

Biosynthesis of gold nanoparticles by two bacterial and fungal strains, Bacillus cereus and Fusarium oxysporum, and assessment and comparison of their nanotoxicity in vitro by direct and indirect assays

Biofabrication of zinc oxide nanoparticle from Ochradenus baccatus leaves: broad-spectrum antibiofilm activity, protein binding studies, and in vivo toxicity and stress studies

In vivo bio-distribution, clearance and toxicity assessment of biogenic silver and gold nanoparticles synthesized from Abutilon indicum in Wistar rats

Effects of biologically produced gold nanoparticles: toxicity assessment in different rat organs after intraperitoneal injection. AMB Express 9

Exposure to low dose ZnO nanoparticles induces hyperproliferation and malignant transformation through activating the CXCR2/NF-kappaB/STAT3/ERK and AKT pathways in colonic mucosal cells

Gold nanoparticles in biology: beyond toxicity to cellular imaging

Does shape matter? Bioeffects of gold nanomaterials in a human skin cell model

Gold-based therapy: from past to present

What do we really know about nanotoxicology of silver nanoparticles in vivo? New aspects, possible mechanisms, and perspectives

Potential risks and benefits of zinc oxide nanoparticles: a systematic review

Environmental Protection Agency) EPA/635

Efficacy and safety evaluation of a chlorine dioxide solution

Humanized COVID-19 decoy antibody effectively blocks viral entry and prevents SARS-CoV-2 infection

Generation of influenza A viruses entirely from cloned cDNAs

Rescue of influenza A virus from recombinant DNA

A simple method of estimating fifty percent endpoints

A Laboratory Manual

We would like to acknowledge the service provided by the Biosafety Level-3 Laboratory of the First Core Laboratory, National Taiwan University College of Medicine, and the Biosafety Level-2 Laboratory of Genomics Research Center, Academia Sinica.

The authors declare no competing interests.

The online version contains supplementary material available at https:// doi. org/ 10. 1038/ s41598-021-87254-3.Correspondence and requests for materials should be addressed to J.-M.F. or P.-C.Y.Reprints and permissions information is available at www.nature.com/reprints.Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.